News · 26 weeks52+267%
2026-03-012026-08-23
Mix2490d
- SEC Filings13(54%)
- Insider6(25%)
- Other3(13%)
- Leadership1(4%)
- Analyst1(4%)
Latest news
25 items- SECSEC Form DEF 14A filed by NexGel IncDEF 14A - NEXGEL, INC. (0001468929) (Filer)
- ANALYSTNexGel downgraded by Maxim GroupMaxim Group downgraded NexGel from Buy to Hold
- SECNexGel Inc filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - NEXGEL, INC. (0001468929) (Filer)
- PRNEXGEL ANNOUNCES LEADERSHIP TRANSITION AND STRATEGIC REVIEW INITIATIVELANGHORNE, Pa., Aug. 20, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL") today announced a series of leadership, governance and strategic initiatives designed to strengthen operational execution, improve liquidity, and enhance long-term shareholder value. The actions include the appointment of Brian Kieser as Interim Chief Executive Officer and the formation of a Special Committee for Strategic Review and Value Creation. Leadership Transition Effective August 21, 2026, Brian Kieser has been appointed Interim Chief Executive Officer of NEXGEL. Following the Company's April 2026 acquisition of certain assets from Celularity, Inc., Mr. Kieser became acti
- SECSEC Form S-1 filed by NexGel IncS-1 - NEXGEL, INC. (0001468929) (Filer)
- SECNexGel Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - NEXGEL, INC. (0001468929) (Filer)
- PRNEXGEL Reports Second Quarter 2026 Financial ResultsLANGHORNE, Pa., Aug. 17, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced its second quarter 2026 financial results for the period ending June 30, 2026. The second quarter of 2026 was a period of significant transformation and preparation for NexGel. Following the completion of our transaction with Celularity, Inc. in mid-April, the Company focused on transitioning employees, integrating sales representatives and customer relationships, and aligning our marketi
- SECSEC Form 10-Q filed by NexGel Inc10-Q - NEXGEL, INC. (0001468929) (Filer)
- SECSEC Form NT 10-Q filed by NexGel IncNT 10-Q - NEXGEL, INC. (0001468929) (Filer)
- SECSEC Form PRE 14A filed by NexGel IncPRE 14A - NEXGEL, INC. (0001468929) (Filer)
- SECNexGel Inc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - NEXGEL, INC. (0001468929) (Filer)
- INSIDERSEC Form 4 filed by Chief Executive Officer Levy Adam R.4 - NEXGEL, INC. (0001468929) (Issuer)
- SECNexGel Inc filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - NEXGEL, INC. (0001468929) (Filer)
- SECSEC Form 8-K filed by NexGel Inc8-K - NEXGEL, INC. (0001468929) (Filer)
- SECSEC Form 8-K filed by NexGel Inc8-K - NEXGEL, INC. (0001468929) (Filer)
- INSIDERChief Executive Officer Levy Adam R. sold $6,519 worth of shares (11,000 units at $0.59), decreasing direct ownership by 3% to 322,692 units (SEC Form 4)4 - NEXGEL, INC. (0001468929) (Issuer)
- SECNexGel Inc filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - NEXGEL, INC. (0001468929) (Filer)
- INSIDERChief Executive Officer Levy Adam R. sold $1,841 worth of shares (3,000 units at $0.61), decreasing direct ownership by 0.89% to 333,692 units (SEC Form 4)4 - NEXGEL, INC. (0001468929) (Issuer)
- INSIDERChief Executive Officer Levy Adam R. sold $3,422 worth of shares (6,000 units at $0.57), decreasing direct ownership by 2% to 336,692 units (SEC Form 4)4 - NEXGEL, INC. (0001468929) (Issuer)
- SECSEC Form DEF 14A filed by NexGel IncDEF 14A - NEXGEL, INC. (0001468929) (Filer)
- PRNEXGEL to Present at Planet MicroCap Conference Las Vegas on June 16th –18thLANGHORNE, Pa., June 04, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced that Adam Levy, Chief Executive Officer, will present at the Planet MicroCap Conference on June 16 – 18, 2026, in Las Vegas, NV. Planet MicroCap Las Vegas 2026Dates: June 16-18, 2026Location: Bellagio Hotel & Casino, Las Vegas, NVBooth: #517Presentation Day and Time: Wednesday, June 17, 2026, at 1:30 P.M. PTPresentation Location: Track 3 - Da Vinci 3Webcast: https://ir.nexgel.com/news-events/events-presentat
- INSIDERChief Executive Officer Levy Adam R. sold $1,172 worth of shares (2,000 units at $0.59), decreasing direct ownership by 0.58% to 342,692 units (SEC Form 4)4 - NEXGEL, INC. (0001468929) (Issuer)
- INSIDERChief Executive Officer Levy Adam R. sold $7,834 worth of shares (13,000 units at $0.60), decreasing direct ownership by 4% to 344,692 units (SEC Form 4)4 - NEXGEL, INC. (0001468929) (Issuer)
- SECSEC Form PRE 14A filed by NexGel IncPRE 14A - NEXGEL, INC. (0001468929) (Filer)
- PRNEXGEL Reports Positive Data from Randomized Single-Center IRB Study to Evaluate the Effectiveness and Safety of a Hydrogel Laser Treatment Patch in Laser Hair Removal with a 95.6% Reduction in Plume ConcentrationThe study concluded that NEXGEL's hydrogel patch significantly reduced laser plume generation and exposure during laser hair removal and the patch was associated with greater hair reduction and reduced pain compared to the control The study was published in Lasers in Surgery and Medicine, 2026 LANGHORNE, Pa., May 19, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced positive data from the randomized, 30-patient, single-center Institutional Review Board (IRB) clinical study, funded
NXGL FAQ
7 questionsWhat does NexGel Inc do?
NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels. Its products are used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. NEXGEL, Inc. was founded in 1997 and is based in Langhorne, Pennsylvania.Where does NXGL stock trade?
NexGel Inc (NXGL) is listed on NASDAQ.What sector and industry is NXGL in?
NexGel Inc operates in the Health Care sector, Medical/Dental Instruments industry.When did NexGel Inc go public?
NexGel Inc (NXGL) completed its IPO in 2021.What are analysts saying about NXGL?
NexGel Inc has had 2 recent analyst actions on file. The most recent action was from Maxim Group: Hold on 2026-08-24. Recent price targets cluster around $600.00.What companies are similar to NXGL?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), BDX (Becton Dickinson and Company), MDLN (Medline Inc.). Compare NXGL side-by-side with any of them on Quantisnow.How can I track NXGL on Quantisnow?
Quantisnow aggregates NexGel Inc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NXGL to receive live email and push alerts on every new disclosure.